bio-rad laboratories inc. - BIO

BIO

Close Chg Chg %
330.37 -10.34 -3.13%

Closed Market

320.03

-10.34 (3.13%)

Volume: 510.29K

Last Updated:

Oct 29, 2025, 3:59 PM EDT

Company Overview: bio-rad laboratories inc. - BIO

BIO Key Data

Open

$331.79

Day Range

315.10 - 334.98

52 Week Range

211.69 - 386.54

Market Cap

$8.94B

Shares Outstanding

27.06M

Public Float

18.30M

Beta

0.97

Rev. Per Employee

N/A

P/E Ratio

28.16

EPS

$11.77

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

244.21K

 

BIO Performance

1 Week
 
-5.97%
 
1 Month
 
4.58%
 
3 Months
 
12.25%
 
1 Year
 
-13.29%
 
5 Years
 
-45.52%
 

BIO Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 8
Full Ratings ➔

About bio-rad laboratories inc. - BIO

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

BIO At a Glance

Bio-Rad Laboratories, Inc.
1000 Alfred Nobel Drive
Hercules, California 94547
Phone 1-510-724-7000 Revenue 2.57B
Industry Medical Specialties Net Income -1,844,200,000.00
Sector Health Technology Employees 7,700
Fiscal Year-end 12 / 2025
View SEC Filings

BIO Valuation

P/E Current 28.158
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 3.611
Price to Book Ratio 1.401
Price to Cash Flow Ratio 20.39
Enterprise Value to EBITDA 17.82
Enterprise Value to Sales 3.498
Total Debt to Enterprise Value 0.153

BIO Efficiency

Revenue/Employee 333,311.688
Income Per Employee -239,506.494
Receivables Turnover 5.512
Total Asset Turnover 0.237

BIO Liquidity

Current Ratio 6.478
Quick Ratio 4.853
Cash Ratio 3.561

BIO Profitability

Gross Margin 53.727
Operating Margin 12.118
Pretax Margin -91.272
Net Margin -71.857
Return on Assets -17.026
Return on Equity -24.091
Return on Total Capital -23.214
Return on Invested Capital -20.483

BIO Capital Structure

Total Debt to Total Equity 20.932
Total Debt to Total Capital 17.309
Total Debt to Total Assets 14.685
Long-Term Debt to Equity 20.273
Long-Term Debt to Total Capital 16.764
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Bio-rad Laboratories Inc. - BIO

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
2.92B 2.80B 2.67B 2.57B
Sales Growth
+14.81% -4.12% -4.67% -3.92%
Cost of Goods Sold (COGS) incl D&A
1.26B 1.23B 1.24B 1.19B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
173.10M 177.20M 192.40M 192.80M
Depreciation
144.70M 152.30M 168.60M 171.60M
Amortization of Intangibles
28.40M 24.90M 23.80M 21.20M
COGS Growth
+13.26% -1.84% +0.49% -4.22%
Gross Income
1.67B 1.57B 1.43B 1.38B
Gross Income Growth
+16.00% -5.84% -8.74% -3.66%
Gross Profit Margin
+56.99% +55.97% +53.58% +53.73%
2021 2022 2023 2024 5-year trend
SG&A Expense
1.11B 1.09B 1.05B 1.07B
Research & Development
258.36M 256.79M 226.93M 253.90M
Other SG&A
853.47M 832.33M 820.62M 814.00M
SGA Growth
+7.86% -2.04% -3.82% +1.94%
Other Operating Expense
- - - -
-
Unusual Expense
(4.86B) 5.21B 1.30B 2.70B
EBIT after Unusual Expense
5.41B (4.73B) (911.95M) (2.39B)
Non Operating Income/Expense
24.82M 62.78M 111.29M 94.20M
Non-Operating Interest Income
18.90M 58.00M 100.90M 82.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
1.55M 38.11M 49.44M 48.90M
Interest Expense Growth
-92.91% +2,357.38% +29.71% -1.09%
Gross Interest Expense
1.55M 38.11M 49.44M 48.90M
Interest Capitalized
- - - -
-
Pretax Income
5.44B (4.70B) (850.10M) (2.34B)
Pretax Income Growth
+10.81% -186.51% +81.93% -175.55%
Pretax Margin
+186.08% -167.87% -31.82% -91.27%
Income Tax
1.19B (1.08B) (212.78M) (498.30M)
Income Tax - Current - Domestic
77.35M 140.76M 85.80M 95.00M
Income Tax - Current - Foreign
32.60M 24.10M 17.40M 28.50M
Income Tax - Deferred - Domestic
1.05B (1.20B) (331.18M) (642.30M)
Income Tax - Deferred - Foreign
32.10M (36.70M) 15.20M 20.50M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
4.25B (3.63B) (637.32M) (1.84B)
Minority Interest Expense
- - - -
-
Net Income
4.25B (3.63B) (637.32M) (1.84B)
Net Income Growth
+11.55% -185.44% +82.43% -189.37%
Net Margin Growth
+145.28% -129.45% -23.86% -71.86%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
4.25B (3.63B) (637.32M) (1.84B)
Preferred Dividends
- - - -
-
Net Income Available to Common
4.25B (3.63B) (637.32M) (1.84B)
EPS (Basic)
142.3319 -121.7907 -21.8194 -65.3647
EPS (Basic) Growth
+11.31% -185.57% +82.08% -199.57%
Basic Shares Outstanding
29.83M 29.79M 29.21M 28.21M
EPS (Diluted)
140.5556 -121.7907 -21.8194 -65.3647
EPS (Diluted) Growth
+11.37% -186.65% +82.08% -199.57%
Diluted Shares Outstanding
30.21M 29.79M 29.21M 28.21M
EBITDA
726.93M 656.52M 576.20M 503.80M
EBITDA Growth
+25.26% -9.69% -12.23% -12.56%
EBITDA Margin
+24.87% +23.43% +21.57% +19.63%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 311.00
Number of Ratings 8 Current Quarters Estimate 2.796
FY Report Date 12 / 2025 Current Year's Estimate 10.007
Last Quarter’s Earnings 2.26 Median PE on CY Estimate N/A
Year Ago Earnings 10.31 Next Fiscal Year Estimate 10.783
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 5 5 5 5
Mean Estimate 2.80 2.62 10.01 10.78
High Estimates 3.04 2.93 10.45 11.50
Low Estimate 2.32 2.14 9.03 9.68
Coefficient of Variance 11.12 12.29 5.67 6.33

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 4 4 5
OVERWEIGHT 0 1 1
HOLD 4 3 3
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Bio-rad Laboratories Inc. - BIO

Date Name Shares Transaction Value
Mar 7, 2025 Roop Kalyan Lakkaraju EVP, Chief Financial Officer 3,891 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 7, 2025 Norman D. Schwartz Chairman & CEO; Director 11,671 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 7, 2025 James J. Barry EVP, President, LSG 2,918 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 7, 2025 Courtney C. Enloe EVP, General Counsel & Sec 1,946 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Jonathan DiVincenzo President & COO 4,863 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Colleen Corey EVP, Global Human Resources 1,946 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Sedat Evran EVP, Global Supply Chain 2,918 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Anette Engelhardt EVP, President, CDG 2,918 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Bio-Rad Laboratories Inc. in the News